NCAPG as a Novel Prognostic Biomarker in Glioma

Abstract

BackgroundNon-SMC condensin I complex subunit G (NCAPG) is expressed in various human cancers, including gliomas. However, its biological function in glioma remains unclear. The present study was designed to determine the biological functions of NCAPG in glioma and to evaluate the association of NCAPG expression with glioma progression.MethodsClinical data on patients with glioma were obtained from The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), the Gene Expression Omnibus (GEO), and the Rembrandt and Gravendeel databases. The correlations among NCAPG expression, pathological characteristics, and clinical outcome were evaluated. In addition, the correlations of NCAPG expression with immune cell infiltration and glioma progression were analyzed.ResultsNCAPG expression was higher in gliomas than in adjacent normal tissues. Higher expression of NCAPG in gliomas correlated with poorer prognosis, unfavorable histological features, absence of mutations in the isocitrate dehydrogenase gene (IDH), absence of chromosome 1p and 19q deletions, and responses to chemoradiotherapy. Univariate and multivariate Cox analysis demonstrated, in addition to patient age, tumor grade, absence of IDH mutations, and absence of chromosome 1p and 19q deletions, NCAPG expression was independently prognostic of overall survival, disease-free survival, and progression-free survival in patients with glioma. In addition, high expression of NCAPG correlated with tumor infiltration of B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells. Gene set enrichment analysis (GSEA) indicated that high NCAPG expression was associated with cell proliferation and immune response-related signaling pathways. NCAPG knockdown in glioma cell lines significantly reduced cell survival, proliferation, and migration.ConclusionNCAPG expression correlates with glioma progression and immune cell infiltration, suggesting that NCAPG expression may be a useful prognostic biomarker for glioma.

The RPL4P4 Pseudogene Is a Prognostic Biomarker and Is Associated with Immune Infiltration in Glioma

“…Immunotherapy plays an increasingly important role in standard cancer treatment, as it can recruit tumor-infiltrating T cells to eradicate tumor cells. In glioma, tumor-infiltrating CD4+ T cells play an important role in immune regulation [ 25 , 26 ]. GSEA showed that RPL4P4 expression was significantly involved in immune signaling pathways.…”

A mini-review of the role of condensin in human nervous system diseases

“…Currently, studies have shown that the subunits of condensin, such as NCAPG, SMC4, and NCAPG2, have been reported to be involved in the glioma pathogenesis. Wherein, NCAPG could be positively related to CDCA2 (cell division cycle-associated protein 2) in glioma, and the over-expression of NCAPG may regulate the cell cycle and promote the proliferation, migration, and invasion of glioma cells (Liang et al, 2016 ; Jiang et al, 2022 ; Jin et al, 2022 ). Meanwhile, NCAPG overexpression can also increase the expression of MHCI and AMAD17 molecules, both of which are located on the tumor surface, thus, assisting in camouflaging the tumor and preventing NK cells from being activated in the immune microenvironment (Zheng et al, 2022 ).…”

MRPS23 is a novel prognostic biomarker and promotes glioma progression

“…The malignant tumor patient prognosis is still poor [ 2 ]. In recent years, the number of tumor patients is gradually increasing, and the effectiveness of treatment is not ideal [ 3 ]. Therefore, the development of effective and specific tumor markers is extremely urgent for the diagnosis and treatment of tumors.…”